Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
556.00 p
21.00 p(2.89%)
At close: 4:00 PM EDT
556.00 p
21.00 p(2.89%)
Day’s Range― - ―
52-Week Range356.00 p - 1,220.00 p
Previous CloseN/A
Volume7.73K
Average Volume (3M)28.51K
Market Cap
£47.59M
Enterprise Value45.81M
Total Cash (Recent Filing)£4.58M
Total Debt (Recent Filing)£1.85M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding6,896,786
10 Day Avg. Volume27,054
30 Day Avg. Volume28,514
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionReducing total debt from approximately 2.95m in 2023 to 2.00m in 2025 lowers the absolute financing burden and represents a constructive balance-sheet direction. If maintained, this could preserve more flexibility for research spending, although leverage remains material relative to equity.
Lower Operating Cash BurnThe reduction in operating cash outflows to approximately 3.45m in 2025 shows some progress in controlling cash consumption. This does not establish self-funding, but sustained improvement could extend financial runway and reduce the pace at which external capital is required.
Specialized Therapeutic FocusA defined focus on hematopoietic stem-cell treatments and hematology/oncology gives the company a clear scientific domain rather than a broad, unfocused development strategy. Concentration in these areas may support deeper expertise and more coherent allocation of research resources over time.
Bears Say
No RevenueThe absence of reported revenue across all provided years means the business has not yet demonstrated commercial product traction or an operating revenue base. Until a candidate or technology generates sales, licensing income, or other recurring receipts, funding remains dependent on future development success and external capital.
Widening LossesNet losses widening to approximately 9.8m in 2025 from 5.6m in 2024 indicates that development spending and operating costs are not yet supported by revenue. Persistent losses can accelerate capital needs, constrain investment choices, and make the path to sustainable profitability more uncertain.
Leverage And Shrinking EquityDebt exceeding equity and the decline in equity from approximately 8.2m in 2021 to 1.2m in 2025 leave a thinner balance-sheet cushion against continued losses. This increases financing pressure and reduces flexibility to fund research or absorb setbacks without additional capital.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 356.00 p and its highest was 1220.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £47.59M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Apr 23, 2027 which is in 182 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Sep 28, 2026. The company reported -1.017 p earnings per share for the quarter.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,896,786 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -1.017 p in its last earnings report. Following the earnings report the stock price went up 3.236%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.79%
12-Months-Change
Fundamentals
Return on Equity
-409.57%
Trailing 12-Months
Asset Growth
121.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―